Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2 (ImbruVeRCHOP)

  • STATUS
    Recruiting
  • End date
    Jan 31, 2025
  • participants needed
    60
  • sponsor
    Prof. Dr. Clemens Schmitt
Updated on 28 January 2022
ct scan
platelet count
renal function
cyclophosphamide
rituximab
vincristine
ejection fraction
prednisone
measurable disease
growth factor
doxorubicin
neutrophil count
follicular lymphoma
b-cell lymphoma
tositumomab
ibrutinib

Summary

The ImbruVeRCHOP-Trials is an Investigator-initiated, single-arm, multi-center, prospective, open phase I/II trial to evaluate the efficacy and feasibility of Ibrutinib and Bortezomib in the therapy of higher-risk DLBCL patients of different molecular subtypes and to correlate outcome with clinical, molecular and imaging-guided response parameters. The protocol includes a safety run-in phase, i.e. the phase I part of the study, to uncover unexpected toxicities that may arise in the context of Ibrutinib and Bortezomib co-administered with the R-CHOP backbone. The safety run-in phase is followed by the phase II part of the trial. About 60 patients will be included over 3 years. Additional 8-11 German university centers will participate in this trial. The study treatment includes a pre-phase therapy with Prednisone and 6 cycles of a combined immuno-chemotherapy with the anti-CD20 antibody Rituximab together with 6 cycles of a chemotherapy consisting of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone plus Bortezomib and Ibrutinib followed by two additional 3-week cycles of Rituximab. Secondary endpoints are the predictive power of subtypes (such as GCB/ABC-"cell-of-origin"), markers of minimal residual disease over time and during-the-study-determined markers (e.g. gene signatures) to identify patients who benefit from this treatment addition.

Description

Cycle 1 (C1): At C1/day d2, there will be a CT- or ultrasound-guided re-biopsy of a lymphoma lesion that is accessible for biopsy without considerable risk for the patient.

Cycle 2 (C2): After C2, a post-Interim CT will be performed (eventually FDG and FLT PET-CT imaging added to the protocol by amendment).

Cycle 3 (C3): At C3/d0 (prior to therapy), there will also be another bone marrow aspirate for MRD follow-up. At C3/d2, there will be a re-biopsy of a lymphoma site in case of a residual lesion by CT that is accessible for biopsy without considerable risk for the patient. Biopsies can be obtained CT- or ultrasound-guided.

End of treatment/post-therapy: The end-of-treatment visit is required for all subjects, irrespective of a completion of all 8 cycles of therapy or exit of the study protocol. It has to be scheduled approximately 4 to 6 weeks after the last cycle. A total of 7 Follow up visits is planned over 30 months of follow up.

Details
Condition Diffuse Large B Cell Lymphoma
Treatment Ibrutinib and Bortezomib + R-CHOP
Clinical Study IdentifierNCT03129828
SponsorProf. Dr. Clemens Schmitt
Last Modified on28 January 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Written informed consent indicating that they understand the purpose of and procedures required for the study, including biomarkers and are willing to participate in the study
Age 61 years and 80 years
CD20-positive diffuse large B-cell lymphoma (DLBCL); including T-cell-rich large B-cell lymphoma, anaplastic large B-cell lymphoma, plasmablastic lymphoma; follicular lymphoma grade 3b or primary transformed follicular lymphoma at initial diagnosis
Lymphoma biopsy native, fresh-frozen for genome-wide transcriptome array or RNA-Seq analyses (gene expression profiling [GEP]) for molecular subtype diagnosis
Willingness to consent to a re-biopsy in C1/day d2, and - in case of a residual lesion by interim CT - in C3/d2 if it can be obtained without inadequate risk
Unfavorable risk profile according to the IPI score (IPI 2)
Performance status (ECOG) 0-2
Bi-dimensionally measurable disease (measurable by CT scan or MRI)
Cardiac ejection fraction 50 % without clinically significant abnormalities
Adequate hematological function: hemoglobin 9 g/dL absolute neutrophil count 1,00/L independent of growth factor support and platelet count 100,000/L or 50,000/L if bone marrow involvement independent of transfusion support in either situation
Adequate renal function as documented by serum creatinine level < 2 x ULN or estimated GFR 40 ml/min/1,73m
Adequate hepatic function (total bilirubin 1,5 x ULN unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin, alanine aminotransferase ALT and aspartate aminotransferase AST 3 x ULN)
Life expectancy > 6 months
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [-hCG]) or urine pregnancy test at screening. Women who are pregnant or breastfeeding are ineligible for this study
Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials. Men must agree to not donate sperm during and after the study. For females, These restrictions apply for 1 month after the last dose of study drug. For males, these restrictions apply for 3 month after the last dose of study drug

Exclusion Criteria

Unable to sign informed consent
Secondary transformed B-NHL or types of NHL other than DLBCL and its subtypes according to WHO classification
Prior therapy for DLBCL
Known central nervous system lymphoma
CNS involvement by lymphoma or any evidence of spinal cord compression. Brain CT/MRI is only mandatory (within 4 weeks prior to study entrance) in case of clinical suspicion of CNS involvement by lymphoma
Major surgery within 4 weeks of study entrance
History of stroke or intracranial hemorrhage within 6 months prior to study entrance
Anticoagulation with Warfarin or equivalent vitamin K antagonists (e.g, Phenprocoumon)
Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure or myocardial infarction within 6 months of Screening or any class 3 or 4 cardiac disease as defined by NYHA
treatment with strong CYP3A inhibitors
Known history of human immunodeficiency virus HIV or active Hepatitis C virus or active Hepatitis B virus infection or any uncontrolled active systemic infection requiring intravenous iv antibiotics
Vaccination with live, attenuated vaccines within 3 weeks of study entrance
History of solid organ transplantation
Pregnant or nursing females
Prior malignancy (except adequately treated basal cell carcinoma and squamous cell carcinoma of the skin, cervical cancer in situ, or any other cancer for which the patient has been in remission for at least 5 years)
Known hypersensitivity or contraindication to any of the study drugs, its ingredients or recombinant human antibodies and contrast agents
Pre-existing polyneuropathy of any kind > grade I
Severe chronic obstructive pulmonary disease with hypoxemia
Current or recent (within the last 30 days prior to enrollment) treatment with another investigational drug or participation in another clinical trial
Evidence of any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug, or patient at high risk from treatment complications
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigators opinion, could compromise the subjects safety, interfere with the absorption or metabolism of ibrutinib capsules or put the study outcomes at undue risk
Any co-existing medical or psychological condition that would compromise the ability to give informed consent
Subjects who are legally detained in an official institution
Subjects who may be dependent on the sponsor, the investigator or the trial sites, have to be exclude from the trial
Lack of willingness to storage and disclosure of pseudonymous disease data in the context of the clinical trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note